Zhejiang CONBA Pharmaceutical Co Ltd (600572) - Net Assets

Latest as of March 2026: CN¥7.37 Billion CNY ≈ $1.08 Billion USD

Based on the latest financial reports, Zhejiang CONBA Pharmaceutical Co Ltd (600572) has net assets worth CN¥7.37 Billion CNY (≈ $1.08 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥10.22 Billion ≈ $1.50 Billion USD) and total liabilities (CN¥2.85 Billion ≈ $417.57 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Zhejiang CONBA Pharmaceutical Co Ltd to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥7.37 Billion
% of Total Assets	72.08%
Annual Growth Rate	16.53%
5-Year Change	-3.25%
10-Year Change	59.35%
Growth Volatility	30.23

Zhejiang CONBA Pharmaceutical Co Ltd - Net Assets Trend (2001–2025)

This chart illustrates how Zhejiang CONBA Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See Zhejiang CONBA Pharmaceutical Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Zhejiang CONBA Pharmaceutical Co Ltd (2001–2025)

The table below shows the annual net assets of Zhejiang CONBA Pharmaceutical Co Ltd from 2001 to 2025. For live valuation and market cap data, see market cap of Zhejiang CONBA Pharmaceutical Co Ltd.

Year	Net Assets	Change
2025-12-31	CN¥7.15 Billion ≈ $1.05 Billion	+3.46%
2024-12-31	CN¥6.91 Billion ≈ $1.01 Billion	-5.95%
2023-12-31	CN¥7.35 Billion ≈ $1.08 Billion	+0.35%
2022-12-31	CN¥7.32 Billion ≈ $1.07 Billion	-0.92%
2021-12-31	CN¥7.39 Billion ≈ $1.08 Billion	+38.19%
2020-12-31	CN¥5.35 Billion ≈ $782.79 Million	+8.23%
2019-12-31	CN¥4.94 Billion ≈ $723.27 Million	-14.67%
2018-12-31	CN¥5.79 Billion ≈ $847.64 Million	-0.87%
2017-12-31	CN¥5.84 Billion ≈ $855.11 Million	+30.20%
2016-12-31	CN¥4.49 Billion ≈ $656.77 Million	-1.69%
2015-12-31	CN¥4.57 Billion ≈ $668.05 Million	+35.46%
2014-12-31	CN¥3.37 Billion ≈ $493.18 Million	+30.05%
2013-12-31	CN¥2.59 Billion ≈ $379.22 Million	+6.18%
2012-12-31	CN¥2.44 Billion ≈ $357.14 Million	+51.39%
2011-12-31	CN¥1.61 Billion ≈ $235.90 Million	-6.06%
2010-12-31	CN¥1.72 Billion ≈ $251.12 Million	+49.56%
2009-12-31	CN¥1.15 Billion ≈ $167.90 Million	+24.77%
2008-12-31	CN¥919.66 Million ≈ $134.58 Million	+7.59%
2007-12-31	CN¥854.74 Million ≈ $125.08 Million	+36.18%
2006-12-31	CN¥627.66 Million ≈ $91.85 Million	+5.47%
2005-12-31	CN¥595.08 Million ≈ $87.08 Million	+5.31%
2004-12-31	CN¥565.05 Million ≈ $82.68 Million	+135.99%
2003-12-31	CN¥239.44 Million ≈ $35.04 Million	+19.27%
2002-12-31	CN¥200.75 Million ≈ $29.38 Million	+10.37%
2001-12-31	CN¥181.89 Million ≈ $26.62 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Zhejiang CONBA Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 10055.6% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥3.53 Billion	50.09%
Other Components	CN¥3.52 Billion	49.91%
Total Equity	CN¥7.05 Billion	100.00%

Zhejiang CONBA Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Zhejiang CONBA Pharmaceutical Co Ltd ranked by their market capitalization.

Company	Market Cap
Atalaya Mining Ltd F:E5S1	$1.53 Billion
Concentrix Corporation NASDAQ:CNXC	$1.53 Billion
Borregaard ASA OL:BRG	$1.53 Billion
Zhejiang Dayuan Pumps Ind Co SHG:603757	$1.53 Billion
Paradeep Phosphates Limited NSE:PARADEEP	$1.53 Billion
Shenzhen Kingdom SCI Tech Co Ltd SHG:600446	$1.53 Billion
Harmonic Inc NASDAQ:HLIT	$1.53 Billion
Peker Gayrimenkul Yatirim Ortakligi AS IS:PEKGY	$1.53 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Zhejiang CONBA Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 6,819,709,642 to 7,046,971,535, a change of 227,261,893 (3.3%).
Net income of 474,363,103 contributed positively to equity growth.
Dividend payments of 383,638,244 reduced retained earnings.
Other factors increased equity by 136,537,034.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥474.36 Million	+6.73%
Dividends Paid	CN¥383.64 Million	-5.44%
Other Changes	CN¥136.54 Million	+1.94%
Total Change	CN¥-	3.33%

Book Value vs Market Value Analysis

This analysis compares Zhejiang CONBA Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.48x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 30.39x to 1.48x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2001-12-31	CN¥0.14	CN¥4.12	x
2002-12-31	CN¥0.15	CN¥4.12	x
2003-12-31	CN¥0.18	CN¥4.12	x
2004-12-31	CN¥0.39	CN¥4.12	x
2005-12-31	CN¥0.41	CN¥4.12	x
2006-12-31	CN¥0.38	CN¥4.12	x
2007-12-31	CN¥0.55	CN¥4.12	x
2008-12-31	CN¥0.54	CN¥4.12	x
2009-12-31	CN¥0.60	CN¥4.12	x
2010-12-31	CN¥0.93	CN¥4.12	x
2011-12-31	CN¥0.79	CN¥4.12	x
2012-12-31	CN¥1.21	CN¥4.12	x
2013-12-31	CN¥1.16	CN¥4.12	x
2014-12-31	CN¥1.35	CN¥4.12	x
2015-12-31	CN¥1.79	CN¥4.12	x
2016-12-31	CN¥1.76	CN¥4.12	x
2017-12-31	CN¥2.26	CN¥4.12	x
2018-12-31	CN¥2.15	CN¥4.12	x
2019-12-31	CN¥1.75	CN¥4.12	x
2020-12-31	CN¥2.00	CN¥4.12	x
2021-12-31	CN¥2.75	CN¥4.12	x
2022-12-31	CN¥2.69	CN¥4.12	x
2023-12-31	CN¥2.74	CN¥4.12	x
2024-12-31	CN¥2.74	CN¥4.12	x
2025-12-31	CN¥2.78	CN¥4.12	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Zhejiang CONBA Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 6.73%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 7.33%
• Asset Turnover: 0.65x
• Equity Multiplier: 1.42x
Recent ROE (6.73%) is below the historical average (12.56%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2001	23.74%	10.94%	0.86x	2.51x	CN¥24.50 Million
2002	21.21%	9.49%	0.95x	2.35x	CN¥22.11 Million
2003	16.87%	8.55%	0.81x	2.45x	CN¥16.32 Million
2004	5.53%	4.75%	0.61x	1.89x	CN¥-23.17 Million
2005	8.17%	5.04%	0.75x	2.16x	CN¥-9.79 Million
2006	15.00%	6.60%	1.02x	2.23x	CN¥28.15 Million
2007	12.54%	8.58%	0.80x	1.83x	CN¥21.52 Million
2008	10.09%	8.40%	0.70x	1.72x	CN¥857.81K
2009	10.15%	7.20%	0.73x	1.93x	CN¥1.49 Million
2010	12.67%	10.31%	0.77x	1.60x	CN¥41.07 Million
2011	19.72%	12.40%	0.76x	2.08x	CN¥138.15 Million
2012	13.60%	10.82%	0.60x	2.09x	CN¥78.26 Million
2013	17.63%	14.27%	0.66x	1.88x	CN¥180.61 Million
2014	19.79%	15.42%	0.57x	2.26x	CN¥273.30 Million
2015	10.63%	8.31%	0.55x	2.31x	CN¥26.22 Million
2016	10.25%	7.33%	0.71x	1.97x	CN¥10.61 Million
2017	12.41%	13.43%	0.56x	1.64x	CN¥138.22 Million
2018	14.43%	11.62%	0.66x	1.90x	CN¥250.17 Million
2019	-7.41%	-5.11%	0.69x	2.11x	CN¥-811.87 Million
2020	9.02%	7.67%	0.64x	1.85x	CN¥-49.32 Million
2021	28.57%	30.72%	0.61x	1.53x	CN¥1.31 Billion
2022	5.18%	5.97%	0.55x	1.58x	CN¥-333.27 Million
2023	8.40%	8.79%	0.60x	1.60x	CN¥-112.53 Million
2024	9.13%	9.55%	0.66x	1.45x	CN¥-59.55 Million
2025	6.73%	7.33%	0.65x	1.42x	CN¥-230.33 Million

Industry Comparison

This section compares Zhejiang CONBA Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $4,041,443,343
Average return on equity (ROE) among peers: 10.73%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Zhejiang CONBA Pharmaceutical Co Ltd (600572)	CN¥7.37 Billion	23.74%	0.39x	$1.53 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$971.04 Million	5.41%	3.98x	$565.97 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$1.33 Billion	6.10%	1.68x	$359.03 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$8.39 Billion	22.09%	0.19x	$4.30 Billion
Livzon Pharmaceutical Group Inc (000513)	$3.01 Billion	11.93%	0.53x	$2.52 Billion
Wedge Industrial Co Ltd (000534)	$1.15 Billion	11.42%	1.59x	$2.41 Billion
Yunnan Baiyao Group Co Ltd (000538)	$1.42 Billion	23.64%	1.01x	$12.64 Billion
Hainan Haiyao Co Ltd (000566)	$445.29 Million	14.73%	0.90x	$715.72 Million
Tus Pharmaceutical Group Co Ltd (000590)	$347.80 Million	3.58%	0.72x	$319.94 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$905.53 Million	2.15%	1.95x	$916.75 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$22.44 Billion	6.25%	0.15x	$3.00 Billion

About Zhejiang CONBA Pharmaceutical Co Ltd

SHG:600572 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.53 Billion

CN¥10.45 Billion CNY

Market Cap Rank

#7296 Global

#1676 in China

Share Price

CN¥4.12

Change (1 day)

+0.24%

52-Week Range

CN¥4.06 - CN¥4.94

All Time High

CN¥10.42